Skyrizi is used to treat certain inflammatory conditions, such as plaque psoriasis. The drug starts working after your first dose. Skyrizi is approved by the Food and Drug Administration (FDA ...

Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

From weight loss to cancer drugs, subcutaneous injections are popular with patients for their convenience, potentially ...

Johnson & Johnson introduced its long-time IL-23 inhibitor plaque psoriasis and psoriatic arthritis ... and AbbVie’s Skyrizi, approved for UC and Crohn’s disease in June, only offer ...

If you live in the United States, you’ve likely seen drug commercials like this one: “If you’re living with moderate to severe plaque psoriasis or active psoriatic arthritis, symptoms can sometimes ...

Stelara was first approved for psoriasis 10 years ago ... as well as new IL-23 inhibitors like AbbVie’s recently-approved Skyrizi (risankizumab), although it seems these are making headway ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

ORKA-001 distinguishes itself from existing treatments such as SKYRIZI through its innovative ... candidate in the competitive landscape of psoriasis treatments, supporting the Buy rating and ...

If you're worried about having enough passive income to maintain your lifestyle during retirement, you're not alone. Having ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

Stock analysts at Zacks Research decreased their FY2024 EPS estimates for AbbVie in a research report issued to clients and investors on Wednesday, January 15th. Zacks Research analyst S. Ganoria now ...